Hyponatremia in cirrhosis

Journal of Hospital Medicine

Volumn 7, Issue SUPPL. 4, 2012, Pages

  Sigal, Samuel H ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ARGIPRESSIN; CONIVAPTAN; DIURETIC AGENT; GLUTAMIC ACID; GLUTAMINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; PLASMA SUBSTITUTE; PROTON PUMP INHIBITOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TOLVAPTAN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

AGED; ALCOHOL CONSUMPTION; ALDOSTERONE BLOOD LEVEL; ASCITES; ASTROCYTE; BACTERIAL PERITONITIS; BACTERIAL TRANSLOCATION; BRAIN DISEASE; CASE REPORT; CELL SWELLING; CELLULITIS; DIET RESTRICTION; DISEASE ASSOCIATION; DRUG WITHDRAWAL; ENDOTOXEMIA; FEMALE; FIBROSIS; FLAPPING TREMOR; HEART FAILURE; HEART OUTPUT; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; INFECTION; IRON OVERLOAD; KIDNEY PERFUSION; LIVER CIRRHOSIS; MICTURITION; PARACENTESIS; PERITONEAL FLUID; POLYDIPSIA; POLYURIA; PORTAL HYPERTENSION; PORTAL VEIN BLOOD; PORTAL VEIN BLOOD FLOW; PRESSORECEPTOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SODIUM ABSORPTION; SODIUM BLOOD LEVEL; SODIUM INTAKE; STELLATE CELL; THIRST; THORAX PRESSURE; VASOCONSTRICTION; XEROSTOMIA;

AGED; FEMALE; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMANS; HYPONATREMIA; LIVER CIRRHOSIS;

EID: 84859488548     PISSN: 15535592     EISSN: 15535606     Source Type: Journal    
DOI: 10.1002/jhm.1915     Document Type: Review

References (25)

1. Ross E, Sigal SH. Managing hyponatremia in cirrhosis. J Hosp Med. 2010; 5( suppl 3): S8-S17.
2. Angeli P, Wong F, Watson H, Ginès P; for the CAPPS Investigators. Hyponatremia in cirrhosis: results of a patient population survey. Hepatology. 2006; 44: 1535-1542.
3. Shah V. Molecular mechanisms of increased intrahepatic resistance in portal hypertension. J Clin Gastroenterol. 2007; 41( suppl 3): S259-S261.
4. Treiber G, Csepregi A, Malfertheiner P. The pathophysiology of portal hypertension. Dig Dis. 2005; 23: 6-10.
5. Iwakiri Y. The molecules: mechanisms of arterial vasodilatation observed in the splanchnic and systemic circulation in portal hypertension. J Clin Gastroenterol. 2007; 41( suppl 3): S288-S294.
6. Iwakiri Y, Groszmann RJ. Vascular endothelial dysfunction in cirrhosis. J Hepatol. 2007; 46: 927-934.
7. Ginès P, Cárdenas A, Arroyo V, et al. Management of cirrhosis and ascites. N Engl J Med. 2004; 350( 16): 1646-1654.
8. Liamis G, Milionis H, Elisf M. A review of drug-induced hyponatremia. Am J Kidney Dis. 2008; 52( 1): 144-153.
9. Solis-Herruzo JA, Moreno D, Gonzalez A, et al. Effect of intrathoracic pressure on plasma arginine vasopressin levels. Gastroenterology. 1991; 101: 607-617.
10. Ginès P, Tito L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterol. 1988; 94: 1493-1502.
11. Ros J, Clària J, To-Figueras J, et al. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology. 2002; 122: 85-93.
12. Bátkai S, Mukhopadhyay P, Harvey-White J, et al. Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in in vivo in cirrhotic rats. Am J Physiol Heart Circ Physiol. 2007; 293: H1689-H1695.
13. Häussinger D, Schliess F. Pathogenetic mechanisms of hepatic encephalopathy. Gut. 2008; 57: 1156-1165.
14. Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008; 359: 1018-1026.
15. Ruf AE, Kremers WK, Chavez LL, et al. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl. 2005; 11: 336-343.
16. Terg R, Gadano A, Cartier M, et al. Serum creatinine and bilirubin predict renal failure and mortality in patients with spontaneous bacterial peritonitis: a retrospective study. Liver Int. 2009; 29: 415-419.
17. Planas R, Montoliu S, Ballesté B, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol. 2006; 4: 1385-1394.
18. Jenq CC, Tsai MH, Tian YC, et al. Serum sodium predicts prognosis in critically ill cirrhotic patients. J Clin Gastroenterol. 2010; 44: 220-226.
19. Heuman DM, Abou-Assi SG, Habib A, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology. 2004; 40: 802-810.
20. Wu CC, Yeung LK, Tsai WS, et al. Incidence and factors predictive of acute renal failure in patients with advanced liver cirrhosis. Clin Nephrol. 2006; 65: 28-33.
21. Ginès P, Guevara M. Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management. Hepatology. 2008; 48( 3): 1002-1010.
22. Schrier RW, Gheorghiade M, Berl T, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006; 355: 2099-2112.
23. Berl T, Quittnat-Pelletier F, Verbalis JG, et al; for the SALTWATER Investigators. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol. 2010; 21: 705-712.
24. Callahan MA, Do HT, Caplan DW, et al. Economic impact of hyponatremia in hospitalized patients: a retrospective cohort study. Postgrad Med. 2009; 121( 2): 186-191.
25. Cyr PL, Slawsky KA, Olchanski N, et al. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure. Am J Health Syst Pharm. 2011; 68( 4): 328-333.